Toward a personalized medicine approach to the management of inflammatory bowel disease

American Journal of Gastroenterology

Volumn 109, Issue 7, 2014, Pages 994-1004

  Mosli, Mahmoud H ^a,c   Sandborn, William J ^b,d   Kim, Richard B ^a   Khanna, Reena ^a,b   Al Judaibi, Bandar ^a,e   Feagan, Brian G ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; GLUCOCORTICOID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR INHIBITOR;

DISEASE ACTIVITY; DRUG MONITORING; ENZYME ASSAY; HUMAN; INFLAMMATORY BOWEL DISEASE; PATIENT MONITORING; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

6-MERCAPTOPURINE; ALGORITHMS; AZATHIOPRINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALIZED MEDICINE; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903940383     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.110     Document Type: Review

References (128)

1. Ladak SS, Chan VW, Easty T et al. Right medication, right dose, right patient, right time, and right route: how do we select the right patient-controlled analgesia (PCA) device? Pain Manag Nurs 2007;8:140-5.
2. Bouguen G, Levesque BG, Feagan BG et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol 2013 (e-pub ahead of print).
3. Gross BN, Ihorst G, Jung M et al. posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 2013;33:1117-25.
4. GonzalezdeCastro D, Clarke PA, Al-Lazikani B et al. P erso n alized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ter 2013;93:252-9.
5. Smith MA, Marinaki AM, Sanderson JD. Pharmacogenomics in the treatment of inf ammatory bowel disease. Pharmacogenomics 2010; 11: 421-37.
6. Coulthard LR, Taylor JC, Eyre S et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 2011;70:98-103.
7. Hlavaty T, Pierik M, Henckaerts L et al. Polymorphisms in apoptosis genes predict response to inf iximab therapy in luminal and f stulizing Crohn's disease. Aliment Pharmacol Ter 2005;22:613-26.
8. Louis E, Vermeire S, Rutgeerts P et al. A positive resp o n se to in f iximab in Crohn disease: association with a higher systemic inf ammation before treatment but not with-308 TNF gene polymorphism. Scand J Gastro-enterol 2002;37:818-24.
9. Mascheretti S, Hampe J, Croucher PJ et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509-15.
10. Mascheretti S, Hampe J, Kuhbacher T et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with inf iximab. Pharmacogenomics J 2002; 2: 127-36.
11. Maxwell JR, Potter C, Hyrich KL et al. Association of the tumour necrosis factor-308 variant with dif erential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008;17:3532-8.
12. Pavy S, Toonen EJ, Miceli-Richard C et al. Tumour necrosis factor alpha-308G-A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010;69:1022-8.
13. Pierik M, Vermeire S, Steen KV et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inf ammatory bowel disease and their association with response to infiximab. Aliment Pharmacol Ter 2004;20: 303-10.
14. Taylor KD, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001;120:1347-55.
15. Urcelay E, Mendoza JL, Martinez A et al. IBD5 polymorphisms in inf am-matory bowel disease: association with response to inf iximab. World J Gastroenterol 2005;11:1187-92.
16. Vermeire S, Louis E, Rutgeerts P et al. NOD2/CARD15 does not inf uence response to inf iximab in Crohn's disease. Gastroenterolog y 2002; 123: 106-11.
17. Hlavaty T, Ferrante M, Henckaerts L et al. Predictive model for the outcome of inf iximab therapy in Crohn's disease based on apoptotic pharma-cogenetic index and clinical predictors. Infamm Bowel Dis 2007;13:372-9.
18. Jurgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to inf iximab in patients with ulcerative colitis. Am J Gastroenterol 2010;105:1811-9.
19. McGovern DP, Gardet A, Torkvist L et al. Genome-wide association identifes multiple ulcerative colitis susceptibility loci. Nat Genet 2010; 42: 33 2-7.
20. Dubinsky MC, Mei L, Friedman M et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inf ammatory bowel disease. Infamm Bowel Dis 2010;16:1357-66.
21. Chen HL, Li LR. Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inf ammatory bowel disease: a meta-analysis. Dig Dis Sci 2012;57:3065-75.
22. Colombel JF, Sandborn WJ, Reinisch W et al. In f iximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: 1383-95.
23. D'Haens G, Baert F, vanAssche G et al. Early combined immunosuppres-sion or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
24. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus implications for clinical pharmacogenomics. Pharmacogenomics 2002;3:89-98.
25. Otterness D, Szumlanski C, Lennard L et al. Human thi opurinemethyl trans-ferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ter 1997;62:60-73.
26. Tai HL, Krynetski EY, Yates CR et al. T iopurine S-methyltransferase defficiency: two nucleotide transitions def ne the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
27. Garat A, Caufez C, Renault N et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol 2008;76:404-15.
28. Ujiie S, Sasaki T, Mizugaki M et al. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2-*24) . Pharma-cogenet Genomics 2008;18:887-93.
29. Appell ML, Wennerstrand P, Peterson C et al. Characterization of anovel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene. Pharmacogenet Genomics 2010;20:700-7.
30. Kham SK, Soh CK, Aw DC et al. TPMT*26 (208F-L), a novel mutation detected in a Chinese. Br J Clin Pharmacol 2009;68:120-3.
31. Loennechen T, Utsi E, Hartz I et al. Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin Pharmacol Ter 2001;70:183-8.
32. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase def ciency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
33. Schaefeler E, Zanger UM, Eichelbaum M et al. Highly multiplexed geno-typing of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in dif erent ethnic groups. Clin Chem 2008;54:1637-47.
34. Schaefeler E, Fischer C, Brockmeier D et al. C o m p re h e n si ve a n a ly sis o f thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407-17.
35. Donnan JR, Ungar WJ, Mathews M et al. Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. Thier Drug Monit 2011;33:192-9.
36. Coulthard SA, Rabello C, Robson J et al. A comparison ofmolecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol 2000;110:599-604.
37. Yeter KC, Afhami M, Brynes RK et al. Aplastic anemia secondary to azathioprine in systemic lupus erythematosus: report of a case with normal thiopurine S-methyltransferase enzyme activity and review of the literature. Lupus 2013;22:1526-8.
38. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosup-pression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
39. Levesque BG, Lofus EV Jr. Initiating azathioprine for Crohn's disease. Clin Gastroenterol Hepatol 2012;10:460-5.
40. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003;3(Suppl 1): S30-8.
41. Sandborn WJ, Tremaine WJ, Wolf DC et al. L ack o f effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastro-enterology 1999;117:527-35.
42. Chisick L, Oleschuk C, Bernstein CN. The utility of thiopurine methyl-transferase enzyme testing in inf ammatory bowel disease. Can J Gastro-enterol 2013;27:39-43.
43. Compagni A, Bartoli S, Buehrlen B et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side efects. Int J Technol Assess Health Care 2008;24:294-302.
44. Priest VL, Begg EJ, Gardiner SJ et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of infammatory bowel disease. Pharmacoeconomics 2006;24:767-81.
45. Relling MV, Gardner EE, Sandborn WJ et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ter 2011;89:387-91.
46. Higgs JE, Payne K, Roberts C et al. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010;11:177-88.
47. Booth RA, Ansari MT, Loit E et al. Assessment of thiopurine S-methyl-transferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011;154:814-23.
48. Rubin DT, Uluscu O, Sederman R. R esp o n se to b io lo gic th erap y in C ro h n 's disease is improved with early treatment: an analysis of health claims data. I n f amm Bowel Dis 2012;18:2225-31.
49. Pittet V, Rogler G, Michetti P et al. Penetrating or stricturing diseases are the major determinants of time to first and repeat resection surgery in Crohn's disease. Digestion 2013;87:212-21.
50. Nasir BF, Grifths L, Nasir A et al. Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. J Clin Gastroenterol 2013;47:242-5.
51. Vermeire S, vanAssche G, Rutgeerts P. Review article: Altering the natural history of Crohn's disease evidence for and against current therapies. Aliment Pharmacol Ter 2007;25:3-12.
52. Ferrante M, Colombel JF, Sandborn WJ et al. Validationofendoscopic activity scores in patients with Crohn's disease based on a post-hoc analysis of data from SONIC. Gastroenterology 2013;145:978-86. e5.
53. Daperno M, D'Haens G, VanAssche G et al. Development and validation of a new, simplif ed endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12.
54. Henckaerts L, VanSteen K, Verstreken I et al. G en etic risk p ro f ling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7: 972-80e2.
55. Waterman M, Xu W, Stempak JM et al. Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. In famm Bowel Dis 2011;17:1936-42.
56. Prideaux L, DeCruz P, Ng SC et al. Serological antibodies in inf ammatory bowel disease: a systematic review. Infamm Bowel Dis 2012;18:1340-55.
57. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
58. Turner D, Mack D, Leleiko N et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282-91.
59. Turner D, Otley AR, Mack D et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
60. Benazzato L, D'Inca R, Grigoletto F et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004;36:461-6.
61. Meyers S, Lerer PK, Feuer EJ et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987;9:50-4.
62. Kumar S, Ghoshal UC, Aggarwal R et al. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol 2004;19:1247-52.
63. Aceituno M, Garcia-Planella E, Heredia C et al. Steroid-refractory ulcera-tive colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Infamm Bowel Dis 2008;14:347-52.
64. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.
65. Ho GT, Mowat C, Goddard CJ et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ter 2004;19:1079-87.
66. Ho GT, Lee HM, Brydon G et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;104:673-8.
67. Carbonnel F, Lavergne A, Lemann M et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39: 1550-7.
68. Naganuma M, Ichikawa H, Inoue N et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010;45:936-43.
69. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with inf iximab: a randomized trial. Ann Intern Med 2007;146:829-38.
70. Lichtenstein GR, Kamm MA, Boddu P et al. E f ect of once-or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102.
71. AbdRahman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and phar-macodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet 2013;52:303-31.
72. Yip JS, Woodward M, Abreu MT et al. How are azathioprine and 6-mer-captopurine dosed by gastroenterologists? Results of a survey of clinical practice. Infamm Bowel Dis 2008;14:514-8.
73. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inf ammatory bowel disease. Gastroenterology 2000;118:705-13.
74. Ooi CY, Bohane TD, Lee D et al. T iopurine metabolite monitoring in paediatric infammatory bowel disease. Aliment Pharmacol Ter 2007;25: 941-7.
75. Reinshagen M, Schutz E, Armstrong VW et al. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53:1306-14.
76. Osterman MT, Kundu R, Lichtenstein GR et al. Association of 6-thiogua-nine nucleotide levels and inf ammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
77. Dassopoulos T, Martin CF, Galanko J et al. T1192 A randomized trial of metabolite-adjusted versus weight-based dosing of azathioprine (AZA) in Crohn's disease (CD) [Clinicaltrials. Gov Identifer Nct00113503]. Gastro-enterology 2009;136.
78. Cufari C, Theoret Y, Latour S et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efcacy and toxicity. Gut 1996;39:401-6.
79. Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite prof les provide a biochemical explanation for 6-MP resistance in patients with inf amma-tory bowel disease. Gastroenterology 2002;122:904-15.
80. Dong XW, Zheng Q, Zhu MM et al. T iopurine S-methyltransferase poly-morphisms and thiopurine toxicity in treatment of inf ammatory bowel disease. World J Gastroenterol 2010; 16: 3187-95.
81. Bastida G, Nos P, Aguas M et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inf ammatory bowel disease. Aliment Pharmacol Ter 2005;22:775-82.
82. Vanasseldonk D.P., Seinen M.L., Deboer N.K., et al. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment, J Crohns Colitis, 2012,6, 95-101.
83. Andersen JB, Szumlanski C, Weinshilboum RM et al. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase defciency. Acta Paediatr 1998;87:108-11.
84. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with inf iximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42; quiz 464.
85. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
86. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
87. Gisbert JP, Panes J. Loss of response and requirement of inf iximab dose intensifcation in Crohn's disease: a review. Am J Gastroenterol 2009;104: 760-7.
88. Candon S, Mosca A, Ruemmele F et al. Clinical and biological consequences of immunization to inf iximab in pediatric Crohn's disease. Clin Immunol 2006;118:11-9.
89. SoutoRodriguez R, Swoger JM, Barreiro-DeAcosta M et al. Maximizing the effect of biologics in infammatory bowel disease. Minerva Gastro-enterol Dietol 2012;58:101-22.
90. Regueiro M, Siemanowski B, Kip KE et al. I n f iximab dose intensification in Crohn's disease. Infamm Bowel Dis 2007;13:1093-9.
91. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance inf iximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
92. Sands BE, Blank MA, Diamond RH et al. Maintenance inf iximab does not result in increased abscess development in f stulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ter 2006;23: 1127-36.
93. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of inf iximab in Crohn's disease. Gastro-enterology 2004;126:402-13.
94. FDA. FDA Approves Adalimumab for Crohn's Diseases. 2007 [19 February 2013]; Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108852.htm.
95. FDA. FDA approves Humira to treat ulcerative colitis. 2012 [cited 19 February 2013]; Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm321650.htm.
96. Baert F, Noman M, Vermeire S et al. In f uence of immunogenicity on the long-term ef cacy of inf iximab in Crohn's disease. N Engl J Med 2003;348:601-8.
97. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedi-cation reduces antibodies to inf iximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.
98. Hanauer SB, Wagner CL, Bala M et al. Incidence and importance of antibody responses to inf iximab af er maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
99. Vermeire S, Noman M, VanAssche G et al. E f ectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infiximab in Crohn's disease. Gut 2007;56:1226-31.
100. VandeCasteele N, Gils A, Singh S et al. A n t i b o d y r e s p o n s e t o i n f iximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013;108:962-71.
101. Lin Z, Bai Y, Zheng P. Meta-analysis: ef cacy and safety of combination therapy of inf iximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol 2011;23:1100-10.
102. Lichtenstein GR, Rutgeerts P, Sandborn WJ et al. A pooled analysis of infections, malignancy, and mortality in inf iximab-and immunomodula-tor-treated adult patients with infammatory bowel disease. Am J Gastro-enterol 2012;107:1051-63.
103. Siegel CA, Marden SM, Persing SM et al. R i s k o f l y m p h o m a a s s o c i a t e d with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastro-enterol Hepatol 2009; 7: 874-81.
104. Karmiris K, Paintaud G, Noman M et al. In f uence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
105. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
106. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6.
107. West RL, Zelinkova Z, Wolbink GJ et al. Immunogenicity negatively inf uences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ter 2008;28:1122-6.
108. Baert F, Noman M, Vermeire S et al. I n f uence of immunogenicity on the long-term ef cacy of inf iximab in Crohn's disease. N Engl J Med 2003;348:601-8.
109. Ordas I, Feagan BG, Sandborn WJ. T erapeutic drug monitoring of tumor necrosis factor antagonists in inf ammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87; quiz e85-6.
110. Ternant D, Mulleman D, Degenne D et al. An enzyme-linked immuno-sorbent assay for therapeutic drug monitoring of infiximab. Thier Drug Monit 2006;28:169-74.
111. Wang SL, Ohrmund L, Hauenstein S et al. Development and validation of a homogeneous mobility shif assay for the measurement of inf iximab and antibodies-to-inf iximab levels in patient serum. J Immunol Methods 2012;382:177-88.
112. Bendtzen K, Geborek P, Svenson M et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor inf iximab. Arthritis Rheum 2006;54:3782-9.
113. Guerra I, Chaparro M, Bermejo F et al. Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inf amma-tory bowel disease. Curr Drug Metab 2011;12:594-8.
114. Aff W, Lofus EV Jr, Faubion WA et al. Clinical utility of measuring inf iximab and human anti-chimeric antibody concentrations in patients with infammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
115. Plasencia C, Pascual-Salcedo D, Garcia-Carazo S et al. The immunogenic-ity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ter 2013;15:R79.
116. Velayos FS, Kahn JG, Sandborn WJ et al. A test-based strategy is more cost effective than empiric dose-escalation for patients with Crohn's disease who lose responsiveness to infiximab. Clin Gastroenterol Hepatol 2013;11:654-66.
117. Steenholdt C, Brynskov J, Tomsen OO et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2013 advance online publication, 22 July 2013 (e-pub ahead of print).
118. Velayos FS, Kahn JG, Sandborn WJ et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to inf iximab. Clin Gastroenterol Hepatol 2013;11:654-66.
119. Brandse JFWM, deBruyn JR, Wolbink G et al. Fecal loss of inf iximab as a cause of lack of response in severe inf ammatory bowel disease. In: European Crohn's and Colitis Organization (ECCO) meeting. Vienna, Austria 2013, p. P500.
120. Schipper LG, vanHulst LT, Grol R et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford) 2010;49:2154-64.
121. Panaccione R, Colombel JF, Louis E et al. E v o l v i n g d e f nitions of remission in Crohn's disease. Infamm Bowel Dis 2013;19:1645-53.
122. Colombel JF, Rutgeerts PJ, Sandborn WJ et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013;12:414-22.
123. Daperno M, Castiglione F, deRidder L et al. Results of the 2nd part Scientif c Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inf ammatory bowel disease. J Crohns Colitis 2011;5:484-98.
124. Bager P, Hentze R, Nairn C. Outpatients with inf ammatory bowel disease (IBD) strongly prefer annual telephone calls from an IBD nurse instead of outpatient visits. Gastroenterol Nurs 2013;36:92-6.
125. Pedersen N, Elkjaer M, Duricova D et al. eHealth: individualisation of inf iximab treatment and disease course via a self-managed web-based solution in Crohn's disease. Aliment Pharmacol Ter 2012;36:840-9.
126. Elkjaer M, Shuhaibar M, Burisch J et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut 2010;59:1652-61.
127. Robinson A, Tompson DG, Wilkin D et al. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001;358:976-81.
128. Papadakis KA. Optimizing the therapeutic potential of azathioprine/ 6-mercaptopurine in the treatment of inf ammatory bowel disease. J Clin Gastroenterol 2003;36:379-81.